your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Diffuse large B cell lymphoma: Management of first relapse or primary refractory disease in medically-fit patients

This algorithm should be used together with related UpToDate topics for diagnosis, staging, and management of relapsed or refractory DLBCL and medical fitness. Treatment of CNS involvement should be initiated prior to systemic therapy.

CAR-T cell: chimeric antigen receptor T cell; HCT: hematopoietic cell transplantation; DLBCL: diffuse large B cell lymphoma; CNS: central nervous system.

* Relapse should be documented by biopsy.

¶ Selection of a salvage chemotherapy regimen is discussed in related UpToDate topics.

Δ Refer to related topic for selection of CAR-T cell agent; in settings where CAR-T cell therapy is not available, autologous HCT is acceptable.

Graphic 139662 Version 1.0